Income tax expense/ (benefit)

12 Months Ended

Jun. 30, 2026

Notes and other explanatory information [abstract]

8.	Income tax expense/ (benefit)

The major components of income tax expense recognized in profit or loss for the periods ended June 30, 2026 and 2025 were:

	2026		2026		2025
	US$		S$		S$

Tax recognized in profit or loss
Current tax expense
Current year		-		-		-
Changes in estimates related to prior years		139,886		179,562		(417,393	)
Tax recognized in profit or loss		139,886		179,562		(417,393	)
Deferred tax expense
Recognition of tax effect of previously unrecognised tax losses		-		-		-
Deferred tax expense		-		-		-
Tax expense/ (benefit) on continuing operation		139,886		179,562		(417,393	)

Relationship between tax expense and accounting loss

A reconciliation between tax expense and the product of accounting loss multiplied by the applicable corporate tax rate for the financial periods ended June 30, 2026 and 2025 were as follows:

	2026			2026			2025
	US$			S$			S$

Loss before tax		(973,673	)		(1,249,833	)		(11,053,571	)

Income tax using the statutory tax rate of 17% (2025: 17%)		(165,524	)		(212,472	)		(1,879,107	)
Effects of:
- Non-deductible expenses		515,894			662,216			1,866,671
- Income tax exemption		(350,370	)		(449,744	)		(17,425	)
- Utilisation of capital allowance		-			-			(449	)
- Deferred tax asset not recognized during the financial year		-			-			30,310
-Underprovision in respect of prior years		139,886			179,562			355
-Overprovision in respect of prior years		-			-			(417,748	)
Income tax expense/(benefit)		139,886			179,562			(417,393	)

Basel Medical Group Ltd. and its Subsidiaries

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For year ended June 30, 2026 and 2025